An observational study in Pancreatic Cancer, sponsored by Wakayama Medical University. Completed at 1 site in Japan. Open to participants aged 20 Years to 85 Years. Per ClinicalTrials.gov, last updated 2020-05-20.
Sponsored by Wakayama Medical University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Pancreatic Neoplasms by Wakayama Medical University — none open to participants now, none under way, none of them phase 3. Pancreatic Neoplasms · Wakayama Medical University.
Among the 10 studies in Pancreatic Neoplasms by Wakayama Medical University, this one is one of 2 that started in 2016, is the only observational one, and was the 9th registered.
3,896 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.
Browse Pancreatic Neoplasms studies →None of the 10 studies in Pancreatic Neoplasms by Wakayama Medical University is open now. The open studies under Pancreatic Neoplasms, anywhere →
Of the 745 Pancreatic Neoplasms studies recruiting now, 478 (64%) set no upper age limit and 151 (20%) stop at 75 or younger; 40 take children under 18; 59 take healthy volunteers.
This study: 20 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2016.
This study's enrollment of 28 is below the median of 200 across 740 observational studies indexed under Pancreatic Neoplasms.
Median enrollment 120 across the 9 interventional studies, 28 across the 1 observational. Of the 7 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Wakayama Medical University is the lead sponsor of 25 studies on the registry; 1 is open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Pancreatic Neoplasms by Wakayama Medical University, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To investigate the correlation between pretreatment ADC value of diffusion MRI and pathologic response in patients with borderline resectable pancreatic carcinoma who undergo neoadjuvant therapy.
Aim: The prediction using diffusion-weighted MRI of the response evaluation in borderline resectable pancreatic cancer.
Study design: Single institution. Single arm. Prospective Phase II Study.
Number of case: 28
Patients: The prediction using dMRI of the response evaluation in borderline resectable pancreatic carcinoma (BRPC) in neoadjuvant therapy.
Disease: Pancreatic carcinoma
Method: To investigate the correlation between pretreatment ADC value of diffusion MRI and pathologic response in patients with borderline resectable pancreatic carcinoma who undergo neoadjuvant therapy.
The correlation between pretreatment ADC value of diffusion MRI and pathologic response evaluated by Evans grade in patients with borderline resectable pancreatic carcinoma (BRPC) who undergo neoadjuvant therapy.
The coefficient of correlation (Peason's r) was r=0.625 in our pilot study in patients with borderline resectable pancreatic cancer. To comfirm the producibility, it is judged as bad if the result is less than 10% from our previous study,the correlation coefficient threshold is 0.56 or more. At the setting of 90%confidential interval as 0.2, the number of case is estimated as 28. Considering unexpected situation, 30 cases is enough to analyze the correlation.
The patients with borderline resectable pancreatic cancer who is expexted to undergo therapy and subsequent radical surgery.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumour. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumour. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Diffusion MRI Patients undergo MRI within 3 weeks before start of neoadjuvant therapy/ 5 weeks after the last dose. The setting of MRI scans for b-values is 0, 50, 1000 s/mm2. The same MRI (the MRI system/scanner Intera Achieva 3.0T from Philips Medical Systems) in the independent institution is used for all patients analyzed on this study. The region of interest is determined by consensus between two experienced MR radiologists in a largest diameter based on images of abdominal CT scans avoiding the vascular area on the image of ADC map. The mean ADC values for each tumor are automatically calculated on the image of ADC map using a tomographic software program.
The statistical analysis of the correlation between pretreatment ADC value of diffusion MRI and pathologic response evaluated by Evans grade in patients with borderline resectable pancreatic carcinoma (BRPC) who undergo neoadjuvant therapy.
Time frame: The time duration of examinations between pretreatment diffusion MRI and histopathological examination is approximately 4 months.
The statistical analysis of the correlation between pretreatment ADC value at the abutment site of BRPC and the rate of tumor cell destruction.
Time frame: The time duration of examinations between pretreatment diffusion MRI and histopathological examination is approximately 4 months.
The statistical analysis of the correlation between posttreatment ADC value at the abutment site of BRPC and the rate of tumor cell destruction.
Time frame: The time duration of examinations between pretreatment diffusion MRI and histopathological examination is approximately 4 months.
The statistical analysis of the correlation between the ratio of posttreatment/pretreatment ADC value at the abutment site of BRPC and the rate of tumor cell destruction.
Time frame: The time duration of examinations between pretreatment diffusion MRI and histopathological examination is approximately 4 months.
The statistical analysis of the correlation between pretreatment ADC value of BRPC tumor in a largest diameter and the rate of tumor cell destruction.
Time frame: The time duration of examinations between pretreatment diffusion MRI and histopathological examination is approximately 4 months.
The statistical analysis of the correlation between the ratio of posttreatment/pretreatment ADC value of BRPC tumor in a largest diameter and the rate of tumor cell destruction.
Time frame: The time duration of examinations between pretreatment diffusion MRI and histopathological examination is approximately 4 months.
The statistical analysis by ROC curve to investigate ADC Cut-off value which predict more than 50% and less than 10% in tumor cell destruction rate.
Time frame: The time duration of examinations between pretreatment diffusion MRI and histopathological examination is approximately 4 months.
The statistical analysis of the correlation between the ratio of posttreatment/pretreatment ADC value of BRPC tumor in a largest diameter and the ratio of posttreatment/pretreatment SUV max in PET-CT.
Time frame: The time duration of examinations between pretreatment diffusion MRI and histopathological examination is approximately 4 months.
The statistical analysis by ROC curve to investigate ADC Cut-off value and SUV max cut-off value which predict survival time after surgery more than 2 years and less than 2 years.
Time frame: Five years after initial therapy.
The statistical analysis of the comparison of the accuracy of prediction for pathological diagnosis at abutment site between the ratio of posttreatment/pretreatment ADC value and CT scan.
Time frame: The time duration of examinations between pretreatment diffusion MRI and histopathological examination is approximately 4 months.
Three correlation between high ADC value/low ADC value/the ratio of posttreatment/pretreatment ADC value and survival time after surgery.
Time frame: The time duration of examinations between pretreatment diffusion MRI and histopathological examination is approximately 4 months.
The statistical analysis of the correlation between high ADC value/low ADC value/the ratio of posttreatment/pretreatment ADC value and decreasing rate of CA19-9 value.
Time frame: The time duration of examinations between pretreatment diffusion MRI and histopathological examination is approximately 4 months.
The statistical analysis of the correlation between tumor's limb sign in diffusion MRI and the rate of tumor cell destruction more than 10%.
Time frame: The time duration of examinations between pretreatment diffusion MRI and histopathological examination is approximately 4 months.
Ran from Jun 2016 to primary completion in Jan 2020, 43 months.
Of 318 non-industry observational studies under Pancreatic Neoplasms, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 182. This study's 43 months is below that.
Counting every sponsor, half of 352 studies reached it within 60 months; a quarter within 34 and three quarters within 182.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Wakayama Medical University